Pure Global
NCT04207970

Evaluating Adapted Structured Clinical Management for People With a Diagnosis of Personality Disorder

Camden and Islington NHS Trust·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Personality Disorders
Drug/Device/Intervention
Adapted Structured Clinical Management
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Camden and Islington NHS Trust
Location
London, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Dec 19, 2019
End date
Aug 31, 2020
Enrollment
27 participants
Primary outcome

Proxy measures of client distress

Summary

Camden and Islington NHS Foundation Trust in London has a Personality Disorder Service (PDS)
 which offers a number of evidence-based interventions to people with a diagnosis of
 Personality Disorder. One team in the PDS, the Community Team, offers an adapted form of
 Structured Clinical Management (SCM; Bateman and Kravitz, 2013). As these adaptations are
 novel, this study aims to formally explore the effectiveness of this intervention, through a
 sample of clients under the team, with outcomes (proxy measures of distress such as inpatient
 admissions) pre- and post- intervention.

ICD-10 classifications
Specific personality disordersOther specific personality disordersPersonality disorder, unspecifiedDisorders of adult personality and behaviourOther specified disorders of adult personality and behaviour
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04207970
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04207970 through Pure Global AI's free database. This phase not specified trial is sponsored by Camden and Islington NHS Trust and is currently Completed. The study focuses on Personality Disorders. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.